FLUORIDE BIOAVAILABILITY

氟化物生物利用度

• 批准号: 6567691
• 负责人: CHARLES Y.C PAK
• 金额: $ 32.14万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6567691
• 关键词: clinical research; female; fluorine; human data; human subject; human therapy evaluation; metabolism disorder chemotherapy; osteoporosis; pharmacokinetics; skeletal disorder chemotherapy; slow release drug; women's health

This study was the initial bioavailability and treatment study utilizing Slow Fluoride for the treatment of osteoporosis aimed at the augmentation of bone mass. This study provided the groundwork for the long term randomized clinical trial of Slow Fluoride treatment of osteoporosis also done at the Dallas GCRC. Data from this study continues to be analyzed thus requiring CDMAS and biostatistical support of the GCRC. Most recently, this study has been utilized for additional bioavailability studies in pre- and post-menopausal normal women.

本研究是利用以下方法进行的初始生物利用度和治疗研究： 慢氟治疗骨质疏松症的目的是 增加骨量。 这项研究为 慢性氟中毒的长期随机临床试验 骨质疏松症也在达拉斯GCRC进行。 本研究数据 继续分析，因此需要CDMAS和生物统计支持 关于GCRC。最近，这项研究已被用于其他 在绝经前和绝经后正常女性中进行的生物利用度研究。